As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.
|Articles|July 27, 2015
Dr. Gregory T. Armstrong on Improved Outcomes for Childhood Cancer Survivors
Author(s)Gregory T. Armstrong, MD, MSCE
Gregory T. Armstrong, MD, MSCE, pediatric oncologist, St. Jude Children's Research Hospital, discusses a trial of 34,000 childhood cancer survivors.
Advertisement
Gregory T. Armstrong, MD, MSCE, pediatric oncologist, St. Jude Children’s Research Hospital, discusses a trial of
Advertisement
Related to this article
A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.
Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.
Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.
Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.
At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.
Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
October 2026 FDA Approvals: 7 Cancer Updates for Oncology Nurses
2
Daraxonrasib and RAS Inhibition: What Oncology Nurses Need to Know
3
Education, Infection Vigilance Define Outpatient Bispecific Care
4
Breast Cancer Diagnosis: How Nurses Can Ease the Emotional Shock
5